<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39373863</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Modeling the Impact of Ensitrelvir on SARS-CoV-2 Dynamics and Its Application for Assessment of Transmission Mitigation of Patients with COVID-19.</ArticleTitle><Pagination><StartPage>2377</StartPage><EndPage>2393</EndPage><MedlinePgn>2377-2393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01046-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Mathematical modeling can provide quantitative understanding of the viral dynamics and viral reduction effects of drugs and enable simulations of the dynamics in various scenarios. In this study, a drug effect model of ensitrelvir was developed to describe the viral reduction effect. Using the model, we also estimated the impact of treatment with ensitrelvir on the reduction in the number of infected patients at the population level in Japan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The drug effect model of ensitrelvir was developed based on a viral dynamic model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a population pharmacokinetic model of ensitrelvir using 10,477 samples of viral load from 1447 patients with coronavirus disease 2019 (COVID-19) in a phase 2/3 study. It was assumed that the drug effect on SARS-CoV-2 promoted the viral clearance depending on the free plasma concentrations. We estimated the impact of ensitrelvir treatment on the reduction in the number of infected patients at the population level in Japan using the susceptible-infectious-recovered-susceptible (SIRS) model including transmission mitigation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The viral reduction effect of ensitrelvir was characterized as a promotion of viral clearance depending on the plasma ensitrelvir concentrations using the E<sub>max</sub> model. The maximum reduction effect was considered to depend on the time from symptom onset to treatment. The maximum transmission mitigation effect was observed when treatment was initiated within 12-24 h of symptom onset, and secondary infections could be reduced by administering ensitrelvir as soon as possible after symptom onset.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The viral reduction by ensitrelvir could be characterized based on the viral dynamics, and the dynamics could be estimated using the drug effect model. Furthermore, the drug effect on population level transmission based on the dynamics could be estimated. Thus, the simulation could be conducted for various conditions.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yamaguchi</LastName><ForeName>Daichi</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0007-9455-5638</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Pharmacokinetics, Shionogi &amp; Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-ku, Osaka, 541-0042, Japan. daichi.yamaguchi@shionogi.co.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Saito</LastName><ForeName>Masaya M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-4840-6515</Identifier><AffiliationInfo><Affiliation>Department of Information Security, Faculty of Information Systems, University of Nagasaki, 1-1-1, Manabino, Nagayocho, Nishisonogigun, Nagasaki, 851-2195, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hata</LastName><ForeName>Ayano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., 1-8, Doshomachi 3-Chome, Chuo-ku, Osaka, 541-0045, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9666-8678</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Pharmacokinetics, Shionogi &amp; Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-ku, Osaka, 541-0042, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazawa</LastName><ForeName>Shogo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0003-6314-5872</Identifier><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., 1-8, Doshomachi 3-Chome, Chuo-ku, Osaka, 541-0045, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Takamichi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4968-2642</Identifier><AffiliationInfo><Affiliation>Biostatistics Center, Shionogi &amp; Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-ku, Osaka, 541-0042, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubota</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1979-4472</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Pharmacokinetics, Shionogi &amp; Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-ku, Osaka, 541-0042, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitanishi</LastName><ForeName>Yoshitake</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Data Science Department, Shionogi &amp; Co., Ltd., 1-8, Doshomachi 3-Chome, Chuo-ku, Osaka, 541-0045, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Ensitrelvir</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Transmission mitigation</Keyword><Keyword MajorTopicYN="N">Viral dynamic model</Keyword></KeywordList><CoiStatement>Daichi Yamaguchi, Ayano Hata, Ryosuke Shimizu, Shogo Miyazawa, Takamichi Baba, Yoshitake Kitanishi, and Ryuji Kubota are employees of Shionogi &amp; Co., Ltd. Masaya M. Saito declares no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373863</ArticleId><ArticleId IdType="pmc">PMC11499563</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01046-6</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01046-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmaceuticals and Medical Devices Agency. List of Approved Drugs April 2004 to March 2024 [Internet]. [cited 26 June 2023]. Available: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html. Accessed 2 Jul 2024.</Citation></Reference><Reference><Citation>Mukae H, Yotsuyanagi H, Ohmagari N, et al. A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob Agents Chemother. 2022;66: e0069722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578433</ArticleId><ArticleId IdType="pubmed">36098519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin Infect Dis. 2023;76:1403–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10110269</ArticleId><ArticleId IdType="pubmed">36477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Yotsuyanagi H, Ohmagari N, Doi Y, et al. A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). Medicine (Baltimore). 2023;102: e33024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9949372</ArticleId><ArticleId IdType="pubmed">36827007</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment [Internet]. [cited 22 Frb 2024]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs. Accessed 9 Apr 2024</Citation></Reference><Reference><Citation>Schiffer JT, Swan DA, Magaret A, et al. Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. Sci Transl Med. 2016;8:324ra15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880060</ArticleId><ArticleId IdType="pubmed">26843190</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Wang X, Song X, Tang S, Rong L. Dynamics of an HIV model with multiple infection stages and treatment with different drug classes. Bull Math Biol. 2016;78:322–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26842389</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AN, Bulitta JB, McSharry JJ, et al. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob Agents Chemother. 2011;55:1747–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067163</ArticleId><ArticleId IdType="pubmed">21263045</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel H, Kukol A. Integrating molecular modelling methods to advance influenza A virus drug discovery. Drug Discov Today. 2021;26:503–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33220433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Ejima K, Iwanami S, et al. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biol. 2021;19: e3001128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984623</ArticleId><ArticleId IdType="pubmed">33750978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Asher J, Cowling BJ, et al. Reducing influenza virus transmission: the potential value of antiviral treatment. Clin Infect Dis. 2022;74:532–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8834654</ArticleId><ArticleId IdType="pubmed">34245250</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher J, Lemenuel-Diot A, Clay M, et al. Novel modelling approaches to predict the role of antivirals in reducing influenza transmission. PLOS Comput Biol. 2023;19: e1010797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9876374</ArticleId><ArticleId IdType="pubmed">36608108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383:309–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang TK, Cowling BJ, Fang VJ, et al. Influenza A virus shedding and infectivity in households. J Infect Dis. 2015;212:1420–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601913</ArticleId><ArticleId IdType="pubmed">25883385</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z, Nugent C, Galvani AP, Krung RM, Meyers LA. Modeling mitigation of influenza epidemics by baloxavir. Nat Commun. 2020;11:2750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265527</ArticleId><ArticleId IdType="pubmed">32487990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li J, Liu H, Hu X, Lin Z, Xiong N. SARS-CoV-2 versus influenza A virus: characteristics and co-treatments. Microorganisms. 2023;11:580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10051779</ArticleId><ArticleId IdType="pubmed">36985154</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi D, Shimizu R, Kubota R. Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer. CPT Pharmacomet Syst Pharmacol. 2024;13:1354–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11330184</ArticleId><ArticleId IdType="pubmed">38783551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi T, Nomura L, Shimizu R, Kubota R. Population pharmacokinetic analysis of ensitrelvir, an inhibitor of 3C-like (3CL) protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection. In: IDWeek 2023. Poster Abstracts, 530.</Citation></Reference><Reference><Citation>Xocova® Tablets 125 mg. Product information 11th edition (Mar 2024).</Citation></Reference><Reference><Citation>Kuroda T, Nobori H, Fukao K, et al. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. J Antimicrob Chemother. 2023;78:946–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10068418</ArticleId><ArticleId IdType="pubmed">36760083</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Metcalf CJM, Stenseth NC, Bjørnstad ON. A general model for the demographic signatures of the transition from pandemic emergence to endemicity. Sci Adv. 2021;7:eabf9040.</Citation><ArticleIdList><ArticleId IdType="pubmed">34380614</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med. 2022;29:taac037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8992231</ArticleId><ArticleId IdType="pubmed">35262737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 omicron in China. Nat Med. 2022;28:1468–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307473</ArticleId><ArticleId IdType="pubmed">35537471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379: e072141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9527398</ArticleId><ArticleId IdType="pubmed">36191948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open. 2022;5: e2228900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9419014</ArticleId><ArticleId IdType="pubmed">36018588</ArticleId></ArticleIdList></Reference><Reference><Citation>Visualizing the data: information on COVID-19 infections. Japanese Ministry of Health, Labour and Welfare. Available: https://covid19.mhlw.go.jp/en/. Accessed 9 Apr 2024.</Citation></Reference><Reference><Citation>McKenzie L, Shoukat A, Wong KO, et al. Inferring the true number of SARS-CoV-2 infections in Japan. J Infect Chemother. 2022;28:1519–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359925</ArticleId><ArticleId IdType="pubmed">35961504</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal SL, Sheiner LB, Boeckmann AJ. NONMEM users guide. Icon development Solutions, Ellicott City, pp 1989–2006.</Citation></Reference><Reference><Citation>Keske Ş, Güney-Esken G, Vatansever C, et al. Duration of infectious shedding of SARS-CoV-2 Omicron variant and its relation with symptoms. Clin Microbiol Infect. 2023;29:221–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9287585</ArticleId><ArticleId IdType="pubmed">35853589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10517426</ArticleId></ArticleIdList></Reference><Reference><Citation>Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26193126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open. 2022;5: e2228008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396366</ArticleId><ArticleId IdType="pubmed">35994285</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO COVID-19 dashboard [Internet]. Available: https://data.who.int/dashboards/covid19/cases?n=. Accessed 9 Apr 2024.</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections [Internet]. Available: https://covid19.mhlw.go.jp/en/. Accessed 9 Apr 2024.</Citation></Reference><Reference><Citation>Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21:147–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasuji H, Takegoshi Y, Kaneda M, et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS ONE. 2020;15: e0243597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725311</ArticleId><ArticleId IdType="pubmed">33296437</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022;28:1491–500.</Citation><ArticleIdList><ArticleId IdType="pubmed">35395151</ArticleId></ArticleIdList></Reference><Reference><Citation>Manica M, Bellis AD, Guzzetta G, et al. Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. Lancet Reg Health Eur. 2022;19: 100446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246701</ArticleId><ArticleId IdType="pubmed">35791373</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S, Cortier T, Charmet T, et al. SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study. Lancet Microbe. 2023;4:e409–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10112864</ArticleId><ArticleId IdType="pubmed">37084751</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal SL. Ways to fit a PK model with some data below the quan-tification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11768292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>